

# 1 **Supplementary Materials and Methods**

## 2 **Plasmids and cells.**

3       The cDNA encoding the Ebola virus (EBOV; Zaire/1976/Mayinga, GenBank:  
4 AF086833.2) mucin-like region (Emuc) from the full-length glycoprotein (amino  
5 acids 312–462) was obtained by gene synthesis (BGI, China). To achieve the normal  
6 modification and localization of Emuc in accordance with the context of viral  
7 infection, Emuc was cloned into the transmembrane TVA (between the amino acid  
8 residues 77 and 78; accession number: L22753) as previously described [1]. The TVA  
9 is a small cell membrane glycoprotein which can serve as the membrane-spanning  
10 receptor for subgroup A avian sarcoma and leukosis virus [2]. Construction of  
11 adenovirus vectors with E1 and E3 deleted ( $\Delta E1/\Delta E3$ ) was carried out as described  
12 previously [3]. Briefly, the Emuc-TVA construct or TVA alone was subcloned into the  
13 plasmid pAdT of the adenovirus generation system in which an EGFP expression  
14 cassette has been inserted as a reporter for conveniently monitoring the subsequent  
15 gene expression, recombinant virus preparation, and transduction. pAdT and the  
16 constructed donor plasmids encoding TVA or Emuc-TVA (named pAdT-TVA or  
17 pAdT-Emuc-TVA, respectively) were then linearized with restriction enzyme *Pme* I  
18 and co-transformed together with the viral DNA ( $\Delta E1/\Delta E3$ ) plasmid into *Escherichia*  
19 *coli* strain BJ5183 by electroporation for homologous recombination. All the cloned  
20 plasmids and recombinants were verified by antibiotic resistance screening, restriction  
21 enzyme analysis, PCR, and/or sequencing.

22       Human embryonic kidney (HEK)293, HEK293A, and African green monkey

23 kidney cells (Vero) were purchased from American Type Culture Collection (ATCC)  
24 and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10%  
25 fetal bovine serum (FBS) (GIBCO) at 37°C in a 5% CO<sub>2</sub> atmosphere.

#### 26 **Transfection and generation of recombinant adenoviruses.**

27 The recombinant plasmids were highly purified by Endofree Plasmid Kit  
28 (Qiagen) and cleaved with restriction enzyme *Pac* I to expose the ITR (inverted  
29 terminal repeats). Using Lipofectamine 2000 (Invitrogen) according to the  
30 manufacturer's instructions, the linearized plasmids were then transfected into  
31 HEK293 cells in which adenoviral E1 functions can be complemented. Transfection  
32 efficiency and viral spread could be monitored by EGFP expression, and recombinant  
33 viruses were harvested by multiple rounds of freezing and thawing. The control  
34 adenovirus expressing EGFP alone and the recombinant adenoviruses encoding EGFP  
35 together with TVA or Emuc-TVA were named ADV, ADV-TVA, and ADV-Emuc-TVA,  
36 respectively.

#### 37 **Viral amplification and purification.**

38 Recombinant adenoviruses were amplified for large-scale production with  $3 \times 10^8$   
39 HEK293A cells in plates. Cells were infected with viruses at a multiplicity of  
40 infection (MOI) of 5. Floating and adherent cells were harvested at 72 hours post  
41 infection (hpi) and resuspended in DMEM supplemented with 5% FBS. After freezing  
42 and thawing, obtained viruses were purified by standard two-step CsCl gradient  
43 ultracentrifugation (Stratagene, La Jolla, CA), and subsequently desalted and  
44 dissolved into a storage buffer (10 mM Tris, pH 8.0, 2 mM MgCl<sub>2</sub> and 4% sucrose).

45 Purified viruses were stored as single use aliquots at -80°C. Virus titers were  
46 determined by tissue culture infectious dose 50 (TCID50) method using 96-well  
47 plates.

#### 48 **Antibodies and fluorescent dyes.**

49 Rabbit polyclonal antibodies to Emuc, TVA, or EGFP were raised against the  
50 target proteins produced from *Escherichia coli*. The secondary antibody for Western  
51 blot was horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Abcam). The  
52 Alexa 488- or 555-conjugated goat anti-rabbit IgG secondary antibodies (Abcam)  
53 were used for immunofluorescence assay. Hoechst 33258 (Beyotime) was used for the  
54 nucleus staining. The PE-conjugated anti-human CD29 (BD Bioscience) and  
55 PE-Cy5-conjugated anti-HLA-I (eBioscience) antibodies used to respectively detect  
56 the cell surface  $\beta$ 1-integrin and HLA-I by flow cytometry were purchased from the  
57 indicated manufacturers.

#### 58 **Western blot analyses.**

59 Cell samples were incubated with the lysis buffer (pH7.4, 150 mM NaCl, 1mM  
60 EDTA, 1% Triton X-100) supplemented with a cocktail protease inhibitor (Roche) at  
61 4°C for 30 minutes. Following centrifugation (13000  $\times$  g) at 4°C for 10 minutes, the  
62 supernatants of the cell lysates were mixed with the sodium dodecyl sulfate (SDS)  
63 sample buffer (25% glycerol, 2.5% SDS, 125 mM Tris, pH6.8, 125 mM dithiothreitol,  
64 0.25% bromophenol blue) and boiled for 10 minutes. Proteins were then separated in  
65 12% SDS polyacrylamide gels and transferred onto polyvinylidene difluoride (PVDF)  
66 membranes (Millipore) at a constant current of 110 mA. After blocking with 5%

67 skimmed milk in Tris-buffered saline-Tween 20 (TBST), the PVDF membranes were  
68 probed with the anti-Emuc or anti-TVA primary antibodies and then the  
69 HRP-conjugated secondary antibody in 1% skimmed milk-TBST. Protein signals  
70 were detected by an enhanced chemiluminescence (ECL) kit (Thermo Fisher  
71 Scientific).

## 72 **Immunofluorescence assays (IFA)**

73 Immunofluorescent staining of cultured adherent cells was performed as  
74 previous described [4, 5]. Briefly, cells infected with ADV-Emuc-TVA, ADV-TVA, or  
75 ADV at a MOI of 1 were fixed by 4% paraformaldehyde (PFA) at 24 hpi. Unless  
76 otherwise specified, cells were then permeabilized by 0.5% Triton X-100 in PBS.  
77 After blocking with 2.5% bovine serum albumin (BSA) (Biosharp) and 2.5% normal  
78 goat serum (Jackson ImmunoResearch) in PBS, cells were incubated with the  
79 anti-Emuc or anti-TVA primary antibodies for 2 hours and then stained with the Alexa  
80 555-conjugated secondary antibody (Abcam) for 1 hour at room temperature. Nuclei  
81 were stained with the Hoechst 33258 dye at room temperature for 5 minutes. Images  
82 were acquired by a Nikon Ti confocal microscope combined with the Image J  
83 software (NIH).

## 84 **Flow cytometry**

85 HEK293A cells were infected with ADV-Emuc-TVA, ADV-TVA, or ADV at a  
86 MOI of 3. At 36 hpi, adherent cells were detached with PBS containing 0.5 mM  
87 EDTA and pooled with the harvested floating cells for the following surface  
88 immunofluorescent staining of live cells. After washing with 1% BSA-PBS, the

89 collections of the floating and adherent cells were resuspended and incubated with 5%  
90 BSA-PBS at 4°C for blocking. Aliquot cell samples were incubated with the  
91 PE-conjugated anti-human CD29 ( $\beta$ 1-integrin) or PE-Cy5-conjugated anti-human  
92 HLA-I antibodies at 4°C for 1 hour, followed by washing. The cell samples were then  
93 assayed by a BD Flow Cytometer (LSR Fortessa). For each sample, 10,000 events in  
94 the live cell gate drawn on forward and side scatter were analyzed. Data were  
95 analyzed by FlowJo software (Tree Star, Inc.). Statistical analyses were performed  
96 with GraphPad Prism version 5 (GraphPad Software Inc., San Diego, CA).

### 97 **Animal experiments**

98 BALB/c mice (n = 3-6, 6-7 week-old females, weight about 18-20 g) were  
99 divided to 4 groups randomly. The mice were infected with the recombinant  
100 adenoviral vectors ( $1 \times 10^8$  PFU in 50  $\mu$ l storage buffer) or mock infected with the  
101 buffer of 50  $\mu$ l by intramuscular injection (i.m.) to the great adductor muscle at inner  
102 side of the hind limbs. While one of the hind limbs was injected, the other one served  
103 as control. Both legs were shaved 24 hours earlier before injection. Animals were  
104 monitored daily for clinical features following the administration. The skeletal  
105 muscles were harvested at 48 hpi (n = 3) or 72 hpi (n = 6), respectively, and fixed  
106 immediately by 4% PFA for at least 24 hours followed by the detection of EGFP  
107 signals in tissues using a PE (CRi) Maestro Imager and the histotomy. The mice  
108 which were not subjected to the following histopathological analyses were euthanized  
109 when they reached an ethical end point.

### 110 **Animal ethics statement**

111 The animal experiments were approved by the Institutional Animal Ethical  
112 Committee of Wuhan Institute of Virology (WIV), Chinese Academy of Sciences  
113 (CAS) (Serial number: WIVA223201401) and conducted in the ABSL-2 containment  
114 space in the Central Animal Laboratory of WIV under the guidelines of the Care and  
115 Use of Laboratory Animals (the Ministry of Science and Technology, China).

### 116 **Immunohistofluorescence and histopathology**

117 The fixed specimens were washed by running water for 30 minutes after placing  
118 in cassettes. All tissues were processed with a graded series of dehydrating agents.  
119 The samples were firstly steeped in a graded ethanol series of 75%, 85%, 95%, 100%,  
120 and then processed with xylene to clear the ethanol in certain periods of time  
121 depending on the thickness of the tissues. Last, samples were embedded in paraffin  
122 and sectioned at 3  $\mu\text{m}$ . Slices were dried for 2 hours at 55°C prior to  
123 immunohistofluorescence assay and hematoxylin and eosin (H&E) staining.

124 The slices were subjected to deparaffinization routinely before the  
125 immunostaining. Then sections were steeped in 3% hydrogen peroxide solution for 30  
126 minutes at room temperature to quench endogenous peroxidase activity.  
127 Microwave-based epitope retrieval was performed in citrate buffer (10mM, pH 6.0) at  
128 100°C for 45 minutes. After blocking in 5% BSA for 2 hours at room temperature,  
129 sections were incubated with the anti-TVA or anti-Emuc primary antibodies at 4°C  
130 overnight. The secondary antibody was the Alexa 488-conjugated goat anti-rabbit  
131 antibody. Following washing, nuclei were stained with the Hoechst 33258 for 10  
132 minutes at room temperature. Section images were captured by Panoramic MIDI

133 Scanner (3DHISTECH).

134 H&E staining was performed by an H&E stain Kit (Nanjing JianCheng  
135 Technology). To quantify the histopathological changes, ten unduplicated visual fields  
136 of muscle or connective tissues for each sample (at the indicated time points post  
137 infection) were chosen, respectively. The degrees of pathological changes in  
138 comparison to mock-infected samples were scored by the standard as described in [6]  
139 with some modifications: 0 = normal; 1 = minimal change (minute quantity of  
140 necrosis or inflammatory cells); 2 = mild change (a small quantity of necrosis or  
141 inflammatory cells); 3 = moderate change (modest quantity of necrosis or  
142 inflammatory cell infiltration); 4 = marked change (large numbers of necrosis or  
143 inflammatory cell infiltration); 5 = severe change (diffuse necrosis or inflammatory  
144 cell infiltration; almost no remaining normal tissue). Statistical analyses were  
145 performed using the GraphPad Prism software.

## 146 **References**

- 147 1 Francica JR, Matukonis MK, Bates P. Requirements for cell rounding and surface protein  
148 down-regulation by Ebola virus glycoprotein. *Virology* 2009; **383**:237-247.
- 149 2 Bates P, Young JAT, Varmus HE. A Receptor for Subgroup-a Rous-Sarcoma Virus Is Related to the  
150 Low-Density-Lipoprotein Receptor. *Cell* 1993; **74**:1043-1051.
- 151 3 He TC, Zhou SB, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating  
152 recombinant adenoviruses. *Proceedings of the National Academy of Sciences of the United States of*  
153 *America* 1998; **95**:2509-2514.
- 154 4 Ning YJ, Wang M, Deng M *et al.* Viral suppression of innate immunity via spatial isolation of

155 TBK1/IKKepsilon from mitochondrial antiviral platform. *Journal of molecular cell biology* 2014;  
156 **6**:324-337.

157 5 Ning YJ, Feng K, Min YQ *et al.* Disruption of type I interferon signaling by the nonstructural protein of  
158 severe fever with thrombocytopenia syndrome virus via the hijacking of STAT2 and STAT1 into  
159 inclusion bodies. *Journal of virology* 2015; **89**:4227-4236.

160 6 Groseth A, Marzi A, Hoenen T *et al.* The Ebola virus glycoprotein contributes to but is not sufficient  
161 for virulence in vivo. *PLoS pathogens* 2012; **8**:e1002847.

162

163